Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Carcinomatous lymphangitis].

S Hominal1, L Falchero, M Perol

  • 1Service de pneumologie, Hôpital de la Croix-Rousse, Lyon.

Presse Medicale (Paris, France : 1983)
|June 15, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mutation type, tyrosine kinase function in normal cell and tyrosine kinase inhibitor activity in cancers.

Scientific reports·2026
Same author

Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Innovative therapeutic cancer vaccine PDC<sup>∗</sup>lung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancer.

ESMO open·2025
Same author

Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysis.

ESMO open·2025
Same author

Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers.

ESMO open·2025
Same author

Treatment sequences in EGFR mutant advanced NSCLC.

Lung cancer (Amsterdam, Netherlands)·2024
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Carcinomatous lymphangitis, a form of lung metastasis, presents with rapid dyspnea and specific CT findings. Early diagnosis and etiological treatment are crucial for improving quality of life and survival.

Area of Science:

  • Oncology
  • Pulmonology
  • Pathology

Context:

  • Carcinomatous lymphangitis is a rare but aggressive form of lung metastasis, comprising approximately 8% of all lung metastasis cases.
  • It is characterized by the presence of tumoral cells within the lymph vessels and lung interstitium.
  • Patients typically present with dyspnea and non-specific chest X-ray findings, often experiencing rapid clinical deterioration.

Purpose:

  • To outline the diagnostic challenges and clinical presentation of carcinomatous lymphangitis.
  • To emphasize the importance of identifying the primary tumor for targeted treatment.
  • To discuss the prognostic implications and management strategies for this condition.

Summary:

  • Diagnosis often relies on biopsy or bronchial brushings, frequently revealing adenocarcinoma.

Related Experiment Videos

  • Characteristic findings on CT scans include millimetric polygonal images in the subpleural area.
  • Respiratory function tests can aid in differential diagnosis, showing mixed ventilation disorders with hypoxemia.

    • Impact:

    • Despite a poor prognosis (median survival of 3 months), identifying the primary lesion allows for etiological treatment, potentially improving quality of life and survival.
    • Symptomatic treatment tailored to the individual patient is essential.
    • This understanding aids clinicians in managing this challenging oncological emergency.